Kim Young-Joon's most recent trade in Rezolute Inc was a trade of 1,230,769 Common Shares done at an average price of $3.2 . Disclosure was reported to the exchange on June 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rezolute Inc | Young-jin Kim | Director | Purchase of securities on an exchange or from another person at price $ 3.25 per share. | 13 Jun 2025 | 1,230,769 | 8,423,386 | - | 3.2 | 3,999,999 | Common Shares |
| Rezolute Inc | Young-jin Kim | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 9,000 | 149,950 | - | 0 | Common Shares | |
| Rezolute Inc | Young-jin Kim | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 5,000 | 5,000 | - | - | Director Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Robert Young Kim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 92,300 | 92,300 | - | - | Stock Option (Right to Buy) | |
| Rezolute Inc | Young-jin Kim | Director | Purchase of securities on an exchange or from another person at price $ 4.00 per share. | 25 Jun 2024 | 1,250,000 | 7,192,617 | - | 4 | 5,000,000 | Common Shares |
| Rezolute Inc | Young-jin Kim | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 25,500 | 140,950 | - | 0 | Common Shares | |
| Rezolute Inc | Young-jin Kim | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 15,000 | 15,000 | - | - | Director Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Young Kim Robert | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 12,000 | 138,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.66 per share. | 05 Feb 2024 | 12,000 | 13,595 | - | 18.7 | 223,920 | Common Stock |
| 4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 05 Feb 2024 | 12,000 | 1,595 | - | 30.1 | 360,600 | Common Stock |
| 4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.78 per share. | 05 Feb 2024 | 6,000 | 7,595 | - | 15.8 | 94,680 | Common Stock |
| 4D Molecular Therapeutics Inc | Kim Young Robert | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 05 Feb 2024 | 6,000 | 7,595 | - | 8.0 | 48,240 | Common Stock |
| 4D Molecular Therapeutics Inc | Kim Young Robert | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 6,000 | 64,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 6,000 | 54,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Kim Young Robert | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 05 Feb 2024 | 6,000 | 1,595 | - | 30.1 | 180,300 | Common Stock |
| 4D Molecular Therapeutics Inc | Robert Kim Young | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 05 Feb 2024 | 6,000 | 1,595 | - | 30.1 | 180,300 | Common Stock |
| 4D Molecular Therapeutics Inc | Kim Young Robert | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 05 Feb 2024 | 552 | 1,043 | - | 30.1 | 16,588 | Common Stock |
| 4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Rezolute Inc | Young-jin Kim | Director | Purchase of securities on an exchange or from another person at price $ 3.80 per share. | 22 Jul 2022 | 78,947 | 78,947 | - | 3.8 | 299,999 | Common Shares |
| Rezolute Inc | Young-jin Kim | Director | Purchase of securities on an exchange or from another person at price $ 1.91 per share. | 22 Jul 2022 | 36,503 | 115,450 | - | 1.9 | 69,859 | Common Shares |
| Rezolute Inc | Young-jin Kim | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) |